CRIS Current Research Information System

GANDOLFI, LETIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.631
NA - Nord America 2.278
AS - Asia 1.819
AF - Africa 102
SA - Sud America 97
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.931
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.247
NL - Olanda 1.988
SG - Singapore 561
DE - Germania 554
VN - Vietnam 518
CN - Cina 381
GB - Regno Unito 297
SE - Svezia 243
HK - Hong Kong 134
IT - Italia 133
RU - Federazione Russa 86
FR - Francia 85
BR - Brasile 74
IN - India 73
UA - Ucraina 71
IE - Irlanda 45
JP - Giappone 37
ZA - Sudafrica 35
TG - Togo 31
FI - Finlandia 28
EE - Estonia 25
KR - Corea 22
CA - Canada 19
PL - Polonia 15
BD - Bangladesh 14
BE - Belgio 11
CI - Costa d'Avorio 11
TH - Thailandia 11
AR - Argentina 10
CH - Svizzera 10
HR - Croazia 9
NG - Nigeria 9
PH - Filippine 9
BG - Bulgaria 8
MX - Messico 8
TR - Turchia 8
ID - Indonesia 7
IR - Iran 7
JO - Giordania 7
LB - Libano 7
ES - Italia 5
IQ - Iraq 5
EG - Egitto 4
TW - Taiwan 4
CL - Cile 3
EC - Ecuador 3
KE - Kenya 3
LT - Lituania 3
MY - Malesia 3
TN - Tunisia 3
AT - Austria 2
DZ - Algeria 2
GR - Grecia 2
JM - Giamaica 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
SA - Arabia Saudita 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CO - Colombia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
ME - Montenegro 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 7.931
Salva come PNG Salva come JPEG
Città #
Eygelshoven 1.285
Kerkrade 666
Singapore 391
Frankfurt am Main 361
Southend 257
Fairfield 246
Ashburn 207
Santa Clara 167
Chandler 151
Houston 132
Woodbridge 129
Hong Kong 124
Seattle 112
San Jose 109
Ann Arbor 105
Wilmington 97
Cambridge 87
Ho Chi Minh City 83
Dong Ket 67
Hanoi 65
Beijing 63
Princeton 62
Boardman 57
Dublin 45
Kyiv 33
Los Angeles 32
New York 32
Lomé 31
Nanjing 30
Berlin 29
Tokyo 28
Helsinki 27
Westminster 27
Hefei 26
Padova 26
Lauterbourg 25
Buffalo 24
Jinan 24
Falkenstein 23
Bremen 21
Seoul 19
Bologna 17
Jacksonville 16
Da Nang 14
Secaucus 14
Council Bluffs 13
Dearborn 13
Shenyang 13
Changsha 12
San Diego 12
Toronto 12
Abidjan 11
Dallas 11
Hangzhou 11
Hebei 11
Brussels 10
Düsseldorf 10
Guangzhou 10
Haiphong 10
Nanchang 10
São Paulo 10
Warsaw 10
Bern 9
Chicago 9
Milan 9
Munich 9
Redondo Beach 9
Turin 9
Abeokuta 8
Columbus 8
Jiaxing 8
The Dalles 8
Amman 7
Hyderabad 7
Istanbul 7
Shanghai 7
Bangkok 6
Falls Church 6
Florence 6
Haikou 6
London 6
Saint Petersburg 6
San Francisco 6
Tianjin 6
Zhengzhou 6
Falconara Marittima 5
Johannesburg 5
Monmouth Junction 5
Norwalk 5
Paris 5
Phoenix 5
Redwood City 5
Sofia 5
Taiyuan 5
Taizhou 5
Bengaluru 4
Bến Tre 4
Lanzhou 4
Quận Bình Thạnh 4
Rio de Janeiro 4
Totale 6.013
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.841
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 251
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 237
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 235
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 221
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 214
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 201
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 199
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 193
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 192
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 179
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 178
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 173
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 170
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 169
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 167
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 164
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 162
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 154
Primary ocular adnexal lymphomas: a retrospective study of 25 patients. 152
Vemurafenib mucosal side-effect. 150
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 147
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 145
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 145
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 139
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor 138
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 127
CAMPYLOBACTER PYLORI IN ABATTOIR WORKERS: IS IT A ZOONOSIS? 37
Endoscopic retrograde cholangiopancreatography (ERCP) in the elderly 35
Cancer of the gastric stump in Italy, 1979–1986 33
Detection of helicobacter pylori-like organisms in the stomach of some food-source animals using a monoclonal antibody 33
A possible source of Campylobacter pylori? ELISA testing of abattoir workers 32
Cancer of the gastric stump in Italy, 1979–1986 29
Detection of helicobacter pylori-like organisms in the stomach of some food-source animals using a monoclonal antibody 27
Gemcitabine 25
IS CAMPYLOBACTER PYLORI A ZOONOSIS? 25
The source of Campylobacter pylori 24
CAMPYLOBACTER PYLORI IN ABATTOIR WORKERS: IS IT A ZOONOSIS? 23
The source of Campylobacter pylori 19
Totale 8.016
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.507
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.507
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021237 0 0 0 0 0 0 0 0 0 24 24 189
2021/2022648 103 36 34 67 52 28 19 32 20 31 118 108
2022/2023687 83 110 51 93 43 65 13 45 78 20 38 48
2023/2024211 30 28 13 34 15 31 26 3 4 12 7 8
2024/2025838 22 76 33 55 206 28 105 16 10 64 23 200
2025/20263.880 91 116 139 77 242 1.395 1.209 68 426 117 0 0
Totale 8.016